Clinical trial NCT02756845: Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors
Official title: A Phase 1, Multi-center, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects With Advanced Non Central Nervous System Tumors That Are Amenable to Direct Injection
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Advanced Non CNS Tumors
Keywords: Non CNS Tumor
Lead sponsor: Amgen
Sponsor class: INDUSTRY
First posted: 2016-04-29
Enrollment: 15
Sex: ALL
Minimum age (years): 2
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Approximately 18 to 24 treated pediatric subjects are expected to be enrolled into 2 cohorts stratified by age (permissible based on the incidence of DLTs, a minimum of 6 subjects/cohort and a minimum of 18 subjects total).

* Cohort A1 (12 to ≤ 21 years of age)
* Cohort B1 (2 to \< 12 years of age) Initially, 3 subjects 12 to ≤ 21 years of age are to be enrolled and treated at 100% of the recommended adult dose regimen of talimogene laherparepvec (cohort A1). The dose level review team (DLRT) will review the safety data of the first 3 subjects in the older age cohort A1 to decide if the younger age cohort B1 can be opened for enrollment. If a DLT occurs in the first 3 DLT-evaluable subjects in the older age cohort (A1 or A2), the younger age cohort will not open until a DLT rate \< 33% is observed with at least 6 DLT-evaluable subjects in the older age cohort (A1 or A2).
Primary purpose: TREATMENT

Brief summary: This is a phase 1 study to evaluate the safety of intralesional talimogene laherparepvec administration in pediatric subjects with advanced non-CNS tumors that are amenable to direct injection

Detailed description: This is a phase 1, multicenter, open-label study of talimogene laherparepvec in pediatric subjects with advanced non-CNS tumors that are amenable to direct injection in the clinical setting. Approximately 18 - 24 pediatric subjects are expected to be enrolled and treated with at least 1 dose of talimogene laherparepvec into 2 cohorts stratified by age. DLT will be evaluated based on at least 9 DLT-evaluable subjects in cohort A1. The DLT evaluation period is 35 days from the initial administration of talimogene laherparepvec.

Eligibility criteria: Inclusion Criteria

* Subject's legally acceptable representative has provided informed consent/assent when the subject is legally too young to provide informed consent/assent and the subject has provided written assent based on local regulations and/or guidelines prior to any study-specific activities/procedures being initiated.
* Should be willing to submit local HSV-1 serostatus within 28 days prior to enrollment.
* Subject must be a candidate for intralesional injection, defined as one or more of the following:

  * at least 1 injectable lesion ≥ 10 mm in longest diameter
  * multiple injectable lesions that in aggregate have a longest diameter of ≥ 10 mm
* Life expectancy \> 4 months from the date of enrollment.
* Male or female subjects 2 to ≤ 21 years of age at the time of informed consent/assent.
* Histologically or cytologically confirmed non-CNS solid tumor that recurred after standard/frontline therapy, or for which there is no standard/frontline therapy available.
* Presence of measurable or non-measurable lesions as defined by irRC-RECIST
* Performance status as per protocol
* Female subject of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to dosing.
* Adequate organ function as defined in protocol

  •Exclusion Criteria
* Diagnosis of leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, or other hematologic malignancy.
* Radiotherapy to the bone marrow within 6 weeks prior to enrollment OR within 3 months prior to enrollment if prior radiotherapy to the craniospinal axis or to at least 60% of the pelvis was received; within 2 weeks prior to enrollment if local palliative radiotherapy was received.
* Primary ocular or mucosal melanoma.
* History of other malignancy within the past 5 years with the following exception:

  • malignancy treated with curative intent and with no known active disease present and has not received chemotherapy for \> 5 years before enrolment and felt to be at low risk for recurrence by the treating physician.
* History or evidence of active autoimmune disease that requires systemic treatment (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
* Active herpetic skin lesions or prior complications of herpetic infection (eg, herpetic keratitis or encephalitis).
* Prior treatment with talimogene laherparepvec or any other oncolytic virus.
* Prior treatment with a tumor vaccine.
* Requires intermittent or chronic treatment with an antiherpetic drug (eg, acyclovir), other than intermittent topical use.
* Expected to require other cancer therapy while on study with the exception of local palliative radiation treatment.
* Has acute or chronic active hepatitis B virus or hepatitis C virus infection or received treatment with nucleotide analogs such as those used in the treatment of hepatitis B virus (eg, lamivudine, adefovir, tenofovir, telbivudine, and entecavir), ribavirin, or interferon alpha within 12 weeks of initiation of study treatment.
* Known or suspected human immunodeficiency virus (HIV) infection.
* Received live vaccine within 28 days prior to enrollment.
* No antiplatelet or anticoagulation medications allowed within 7 days prior totalimogene laherparepvec injection except low-dose heparin needed to maintain venous catheter patency.
* Female subject is pregnant or breast-feeding, or planning to become pregnant during study treatment and through 3 months after the last dose of talimogene laherparepvec.
* Female subject of childbearing potential who is unwilling to use acceptable method(s) of effective contraception during study treatment and through 3 months after the last dose of talimogene laherparepvec. Note: Acceptable methods of effective contraception are defined in the informed consent/assent form. Where required by local laws and regulations, additional country-specific contraception requirements may be outlined in a country-specific protocol supplement at the end of the Appendix Section of protocol.
* Subject has known sensitivity to any of the products or components to be administered during dosing.
* Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject and investigator's knowledge.
* History or evidence of any psychiatric disorder, substance abuse or any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
* Subject who is unwilling to minimize exposure with his/her blood or other body fluids to individuals who are at higher risks for HSV-1 induced complications (immunosuppressed individuals, HIV-positive individuals, pregnant women, or children under the age of 1 year) during talimogene laherparepvec treatment and through 28 days after the last dose of talimogene laherparepvec.
* Evidence of clinically significant immunosuppression such as the following:

  * primary immunodeficiency state such as severe combined immunodeficiency disease
  * concurrent opportunistic infection
  * receiving systemic immunosuppressive therapy (\> 2 weeks prior to enrollment), including oral steroid doses (with the exception of maintenance physiologic replacement). Subjects who require intermittent use of steroids for inhalation or local steroid injection will not be excluded from the study
  * less than 6 months from autologous bone marrow transplant or stem cell infusion
  * history of allogeneic bone marrow transplant
* History or evidence of xeroderma pigmentosum.
* Sexually active subjects and their partners unwilling to use a male or female latex condom to avoid potential viral transmission during sexual contact while on treatment and within 30 days after treatment with talimogene laherparepvec. For those with latex allergies, polyurethane condoms may be used.
* Prior chemotherapy, treatment dose radiotherapy, or biological cancer therapy within 14 days prior to enrollment or has not recovered to Common Terminology Criteria for Adverse Events version 4.0 (CTCAE) grade 1 or better from adverse event due to cancer therapy administered more than 14 days prior to enrollment.
* CNS tumor or clinically active brain metastases (patient with a history of treated brain metastases are eligible if there is radiographic evidence of improvement upon the completion of CNS-directed therapy and no evidence of interim progression between the completion of CNS-directed therapy and the screening radiographic study).
* Currently receiving treatment in another investigational device or drug study, or less than 14 days since ending treatment on another investigational device or drug study(ies) or has not recovered to CTCAE version 4.0 grade 1 or better from adverse event due to other investigational device or drug study administered more than 14 days prior to enrollment. Other investigational procedures while participating in this study are excluded.
* Major surgery ≤ 14 days prior to enrollment or has not recovered to CTCAE version 4.0 grade 1 or better from adverse event due to surgery performed more than 14 days prior to enrollment.

Primary outcomes:
measure: Percentage of Participants Who Experienced a Dose-limiting Toxicity (DLT)
timeFrame: Day 1 to Day 35
Secondary outcomes:
measure: Overall Response Rate (ORR)
timeFrame: Every 12 weeks until the end of follow-up; maximum duration of follow-up was 54.51 months
measure: Duration of Response (DOR)
timeFrame: Every 12 weeks until the end of follow-up; maximum duration of follow-up was 54.51 months
measure: Time to Response (TTR)
timeFrame: Every 12 weeks until the end of follow-up; maximum duration of follow-up was 54.51 months
measure: Time to Progression (TTP)
timeFrame: Every 12 weeks until the end of follow-up; maximum duration of follow-up was 54.51 months
measure: Progression Free Survival (PFS)
timeFrame: Every 12 weeks until the end of follow-up; maximum duration of follow-up was 54.51 months
measure: Overall Survival (OS)
timeFrame: Every 12 weeks until the end of follow-up; maximum duration of follow-up was 54.51 months
Other outcomes:
Locations:
city: Wilmington
country: United States
facility: AI Dupont Hospital for Children
state: Delaware
city: Jacksonville
country: United States
facility: Nemours du Pont Hospital in Florida
state: Florida
city: Chicago
country: United States
facility: Ann and Robert H Lurie Childrens Hospital of Chicago
state: Illinois
city: Indianapolis
country: United States
facility: Riley Hospital for Children
state: Indiana
city: Detroit
country: United States
facility: Childrens Hospital of Michigan
state: Michigan
city: New York
country: United States
facility: Columbia University Medical Center
state: New York
city: Cincinnati
country: United States
facility: Cincinnati Childrens Hospital Medical Center
state: Ohio
city: Columbus
country: United States
facility: Nationwide Childrens Hospital
state: Ohio
city: Philadelphia
country: United States
facility: Childrens Hospital of Philidelphia
state: Pennsylvania
city: Gent
country: Belgium
facility: Universitair Ziekenhuis Gent
city: Montreal
country: Canada
facility: Centre Hospitalier Universitaire Sainte Justine
state: Quebec
city: Lyon cedex 08
country: France
facility: Institut Hematologie et Oncologie Pediatrique
city: Marseille cedex 5
country: France
facility: Centre Hospitalier Universitaire de Marseille - Hopital de la Timone
city: Paris
country: France
facility: Institut Curie
city: Roma
country: Italy
facility: IRCCS Ospedale Pediatrico Bambino
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen del Rocio
state: Andalucía
city: Barcelona
country: Spain
facility: Hospital Universitari Vall d Hebron
state: Cataluña
city: Esplugues de Llobregat
country: Spain
facility: Hospital Sant Joan de Deu
state: Cataluña
city: Valencia
country: Spain
facility: Hospital Universitari i Politecnic La Fe
state: Comunidad Valenciana
city: Madrid
country: Spain
facility: Hospital Universitario Infantil Niño Jesus
city: Basel
country: Switzerland
facility: Universitaets-Kinderspital beider Basel
city: Zuerich
country: Switzerland
facility: Universitaets-Kinderspital
Study officials:
affiliation: Amgen
name: MD
role: STUDY_DIRECTOR
References:
citation: Moreno L, Teira P, Croop JM, Gerber NU, Andre N, Aerts I, Gros Subias L, De Wilde B, Bautista F, Turpin B, Kunduri S, Hamidi A, Lawrence T, Streby KA. A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors. Front Pediatr. 2023 May 24;11:1183295. doi: 10.3389/fped.2023.1183295. eCollection 2023.